In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.1 below Armata Pharmaceuticals Inc average.

Within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Armata Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 3803.

Explain Quick Ratio?
How much Cash & cash equivalents ARMP�s has?
What are ARMP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ARMP Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	108.35 %	-95.81 %	-90.92 %	18.4 %	-2.51 %
Y / Y Cash & cash equivalent Change	453.42 %	-59.33 %	-6.49 %	-13.91 %	-83.61 %
Quick Ratio MRQ	0.1	1.03	1.98	0.11	0.04
ARMP's Total Ranking	# 3803	# 0	# 992	# 3105	# 3556
Seq. Current Liabilities Change	5298.04 %	5.75 %	-96.87 %	16.54 %	8.63 %
Seq. Cash & cash equivalent Change	403.83 %	-45.28 %	-41.12 %	240.94 %	-62.97 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 139
Healthcare Sector	# 854
Overall Market	# 3803

Quick Ratio Statistics
High	Average	Low
16.02	3.29	0.04
(Mar 31 2014)		(Jun 30 2025)

Financial Statements
Armata Pharmaceuticals Inc 's Current Liabilities	$ 250 Millions	Visit ARMP's Balance sheet
Armata Pharmaceuticals Inc 's Cash & cash equivalent	$ 24 Millions	Visit ARMP's Balance sheet
Source of ARMP's Sales		Visit ARMP's Sales by Geography

Cumulative Armata Pharmaceuticals Inc 's Quick Ratio

ARMP's Quick Ratio for the trailling 12 Months

ARMP Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	0.53 %	-32.77 %	-6.19 %	16.86 %	59.7 %
Y / Y Cash & cash equivalent TTM Growth	22.86 %	-49.59 %	-56.49 %	-57.8 %	-58.28 %
Quick Ratio TTM	0.13	0.12	0.11	0.1	0.11
Total Ranking TTM	# 3195	# 3805	# 2946	# 2930	# 2768
Seq. Current Liabilities TTM Growth	48.36 %	-28.24 %	-10.47 %	5.48 %	-0.77 %
Seq. Cash & cash equivalent TTM Growth	60.33 %	-17.57 %	-1.51 %	-5.62 %	-34.21 %

Quick ratio ranking by company, industry and sector >> Back to ARMP Financial Strength Comparisons >> Go to Compare ARMP Quick Ratio to its Competitors

On the trailing twelve months basis ARMP Cash & cash equivalent more than doubled by 453.42 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Armata Pharmaceuticals Inc 's Quick Ratio to 0.13, Quick Ratio remained below ARMP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Armata Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 0 to 4104.

Explain Quick Ratio?
How much Cash & cash equivalents ARMP�s has?
What are ARMP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 911
Within the Market	# 3803

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.35	2.52	0.1
(Dec 31 2014)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions
Phoenix Biotech Acquisition Corp	0.03	$ 0.888 Millions	$ 32.405 Millions

Date modified: 2026-09-04T10:01:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.